These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

685 related items for PubMed ID: 18852441

  • 1. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L.
    Neurology; 2008 Oct 14; 71(16):1261-7. PubMed ID: 18852441
    [Abstract] [Full Text] [Related]

  • 2. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
    Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, Brinkmann V.
    Neurology; 2010 Aug 03; 75(5):403-10. PubMed ID: 20592255
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
    Chiba K.
    Pharmacol Ther; 2005 Dec 03; 108(3):308-19. PubMed ID: 15951022
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kümpfel T, Buck D, Hohlfeld R, Berthele A, Hemmer B.
    Neurology; 2011 Apr 05; 76(14):1214-21. PubMed ID: 21464424
    [Abstract] [Full Text] [Related]

  • 11. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo.
    Wolf AM, Eller K, Zeiser R, Dürr C, Gerlach UV, Sixt M, Markut L, Gastl G, Rosenkranz AR, Wolf D.
    J Immunol; 2009 Sep 15; 183(6):3751-60. PubMed ID: 19692647
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
    Lan YY, Tokita D, Wang Z, Wang HC, Zhan J, Brinkmann V, Thomson AW.
    Transpl Immunol; 2008 Nov 15; 20(1-2):88-94. PubMed ID: 18694829
    [Abstract] [Full Text] [Related]

  • 14. FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis.
    Fujii R, Kanai T, Nemoto Y, Makita S, Oshima S, Okamoto R, Tsuchiya K, Totsuka T, Watanabe M.
    Am J Physiol Gastrointest Liver Physiol; 2006 Aug 15; 291(2):G267-74. PubMed ID: 16574986
    [Abstract] [Full Text] [Related]

  • 15. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice.
    Klingenberg R, Nofer JR, Rudling M, Bea F, Blessing E, Preusch M, Grone HJ, Katus HA, Hansson GK, Dengler TJ.
    Arterioscler Thromb Vasc Biol; 2007 Nov 15; 27(11):2392-9. PubMed ID: 17761943
    [Abstract] [Full Text] [Related]

  • 16. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.
    Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG.
    Nature; 2004 Jan 22; 427(6972):355-60. PubMed ID: 14737169
    [Abstract] [Full Text] [Related]

  • 17. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.
    Papadopoulos D, Rundle J, Patel R, Marshall I, Stretton J, Eaton R, Richardson JC, Gonzalez MI, Philpott KL, Reynolds R.
    J Neurosci Res; 2010 Feb 01; 88(2):346-59. PubMed ID: 19658199
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of donor-derived T cells trafficking into target organs by FTY720 during acute graft-versus-host disease in small bowel transplantation.
    Song J, Ito T, Matsuda C, Miao G, Tanemura M, Nishida T, Nozawa M, Matsuda H, Sawa Y.
    Clin Exp Immunol; 2006 Oct 01; 146(1):85-92. PubMed ID: 16968402
    [Abstract] [Full Text] [Related]

  • 19. Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients.
    Böhler T, Schütz M, Budde K, Neumayer HH, Waiser J.
    Int Immunopharmacol; 2007 Jan 01; 7(1):88-95. PubMed ID: 17161821
    [Abstract] [Full Text] [Related]

  • 20. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo.
    Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K.
    J Immunol; 1998 Jun 01; 160(11):5493-9. PubMed ID: 9605152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.